Cargando…
PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis
Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignant disease with 5-year survival rate of less than 6%. Activating mutations of Kras (mu-Kras) are often detected in most of PDAC patients. Although it has been known that oncogenic Kras is the driver of pancreatic cancer initiation and develop...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132349/ https://www.ncbi.nlm.nih.gov/pubmed/30214681 http://dx.doi.org/10.18632/oncotarget.25127 |
_version_ | 1783354301383442432 |
---|---|
author | Wang, Peipei Wei, Dapeng Zhang, Hongmei Chen, Jiao Zhang, Dingding Ganapathy, Suthakar Isakson, Pauline Chen, Changyan Zhu, Tongbo |
author_facet | Wang, Peipei Wei, Dapeng Zhang, Hongmei Chen, Jiao Zhang, Dingding Ganapathy, Suthakar Isakson, Pauline Chen, Changyan Zhu, Tongbo |
author_sort | Wang, Peipei |
collection | PubMed |
description | Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignant disease with 5-year survival rate of less than 6%. Activating mutations of Kras (mu-Kras) are often detected in most of PDAC patients. Although it has been known that oncogenic Kras is the driver of pancreatic cancer initiation and development, the underlying mechanisms by which mu-Kras promotes PDAC remain poorly understood. Here, we identify that PKCι is one of the crucial factors for supporting the survival of pancreatic cancer cells expressing mu-Kras. Our study demonstrates that after the knockdown of PKCι, the expression of the transcriptional co-activator YAP1 is decreased, which hinders the expression of the downstream target gene Mcl-1, and subsequently sensitizes pancreatic cancer MiaPaCa and PANC-1 cells experssing mu-Kras to apoptosis. In comparison, the suppression of PKCι has little impact on the viability of non-neoplastic pancreatic HPDE6-C7 cells. Moreover, the transient overexpression of oncogenic Kras in HPDE6-C7 elevates the expression of PKCι and YAP1 concomitantly. The upregulated YAP1 in HPDE6-C7/ mu-Kras cells is abolished once PKCι is suppressed, suggesting the linear relationship among mu-Kras, PKCι and YAP1. This phenomenon is further proven by the co-upregulation of PKCι and YAP1 in HPDE6-C7 cells stably transfected with mu-Kras. Taken together, our findings suggest that PKCι acts through promoting YAP1 function to promote the survival of pancreatic cancer cells expressing mu-Kras. It appears that targeting PKCι-YAP1 signaling is a feasible strategy for developing new therapeutics for treating pancreatic cancer patients. |
format | Online Article Text |
id | pubmed-6132349 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-61323492018-09-13 PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis Wang, Peipei Wei, Dapeng Zhang, Hongmei Chen, Jiao Zhang, Dingding Ganapathy, Suthakar Isakson, Pauline Chen, Changyan Zhu, Tongbo Oncotarget Research Paper Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignant disease with 5-year survival rate of less than 6%. Activating mutations of Kras (mu-Kras) are often detected in most of PDAC patients. Although it has been known that oncogenic Kras is the driver of pancreatic cancer initiation and development, the underlying mechanisms by which mu-Kras promotes PDAC remain poorly understood. Here, we identify that PKCι is one of the crucial factors for supporting the survival of pancreatic cancer cells expressing mu-Kras. Our study demonstrates that after the knockdown of PKCι, the expression of the transcriptional co-activator YAP1 is decreased, which hinders the expression of the downstream target gene Mcl-1, and subsequently sensitizes pancreatic cancer MiaPaCa and PANC-1 cells experssing mu-Kras to apoptosis. In comparison, the suppression of PKCι has little impact on the viability of non-neoplastic pancreatic HPDE6-C7 cells. Moreover, the transient overexpression of oncogenic Kras in HPDE6-C7 elevates the expression of PKCι and YAP1 concomitantly. The upregulated YAP1 in HPDE6-C7/ mu-Kras cells is abolished once PKCι is suppressed, suggesting the linear relationship among mu-Kras, PKCι and YAP1. This phenomenon is further proven by the co-upregulation of PKCι and YAP1 in HPDE6-C7 cells stably transfected with mu-Kras. Taken together, our findings suggest that PKCι acts through promoting YAP1 function to promote the survival of pancreatic cancer cells expressing mu-Kras. It appears that targeting PKCι-YAP1 signaling is a feasible strategy for developing new therapeutics for treating pancreatic cancer patients. Impact Journals LLC 2018-08-28 /pmc/articles/PMC6132349/ /pubmed/30214681 http://dx.doi.org/10.18632/oncotarget.25127 Text en Copyright: © 2018 Wang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Wang, Peipei Wei, Dapeng Zhang, Hongmei Chen, Jiao Zhang, Dingding Ganapathy, Suthakar Isakson, Pauline Chen, Changyan Zhu, Tongbo PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis |
title | PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis |
title_full | PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis |
title_fullStr | PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis |
title_full_unstemmed | PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis |
title_short | PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis |
title_sort | pkcι and yap1 are crucial in promoting pancreatic tumorigenesis |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132349/ https://www.ncbi.nlm.nih.gov/pubmed/30214681 http://dx.doi.org/10.18632/oncotarget.25127 |
work_keys_str_mv | AT wangpeipei pkciandyap1arecrucialinpromotingpancreatictumorigenesis AT weidapeng pkciandyap1arecrucialinpromotingpancreatictumorigenesis AT zhanghongmei pkciandyap1arecrucialinpromotingpancreatictumorigenesis AT chenjiao pkciandyap1arecrucialinpromotingpancreatictumorigenesis AT zhangdingding pkciandyap1arecrucialinpromotingpancreatictumorigenesis AT ganapathysuthakar pkciandyap1arecrucialinpromotingpancreatictumorigenesis AT isaksonpauline pkciandyap1arecrucialinpromotingpancreatictumorigenesis AT chenchangyan pkciandyap1arecrucialinpromotingpancreatictumorigenesis AT zhutongbo pkciandyap1arecrucialinpromotingpancreatictumorigenesis |